Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Voss

Showing results (321-330 of 419) with videos related to

Pageof 42
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell CarcinomaKyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
European Urology Focus|March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint TherapyAndrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
European Urology Focus|September 28, 2017
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell CarcinomaJozefina Casuscelli, Maria F Becerra, Brandon J Manley, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 TrialMeredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease ProgressionJulian Marcon, Renzo G DiNatale, Alejandro Sanchez, et al.
Pageof 42

Showing results (321-330 of 419) with videos related to

Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell CarcinomaKyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
European Urology Focus|March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint TherapyAndrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
European Urology Focus|September 28, 2017
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell CarcinomaJozefina Casuscelli, Maria F Becerra, Brandon J Manley, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 TrialMeredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease ProgressionJulian Marcon, Renzo G DiNatale, Alejandro Sanchez, et al.
Pageof 42